Clinical Overview
Today is · Good morning, Dr. James
47
Analyses Today
↑ 12% vs yesterday
94.7%
AI Accuracy Rate
↑ FDA Validated
3
Pending Alerts
Drug interactions flagged
8
Patients Today
2 high-priority
Recent Activity Last 24 hours
09:42 AM
Chest X-Ray Analysis — Patient #4821
AI detected no acute abnormalities. 96% confidence. Report generated.
09:15 AM
Drug Interaction Alert — Warfarin + Aspirin
Severe interaction detected. Requires immediate review before prescribing.
08:50 AM
Lab Results Interpreted — Patient #3901
Mild leukocytosis + borderline glucose. Prediabetes screening recommended.
08:20 AM
High-Risk Assessment — Patient #2247
10-year CVD risk at 15.2%. Initiated statin therapy discussion.
Yesterday 4:30 PM
Clinical Note Generated — Patient #5012
AI-drafted SOAP note reviewed and signed. Uploaded to EMR.
Quick Tools
System Status
Claude AI Engine● Online
Drug Database● Synced
Imaging AI Model● Active
FHIR EMR Sync● Pending
Last Backup2 mins ago
AI Clinical Consultant
Powered by Claude · Ask anything clinical — differential diagnosis, treatment protocols, drug queries, guidelines
Claude Clinical AI
Evidence-based · Real-time · Confidential
GPT-4 class
Quick prompts:
🩺 Active Patient Context
Patient: #4821 · M, 42 yrs
Chief Complaint: Persistent cough, fever
Allergies: Penicillin (rash)
Current Meds: Warfarin 5mg, Lisinopril 10mg
Comorbidities: AF, Hypertension
📚 Guidelines Cited
ACC/AHA 2023
Hypertension Guidelines
Hypertension Guidelines
WHO 2023
TB Clinical Protocols
TB Clinical Protocols
NICE 2024
Type 2 Diabetes Management
Type 2 Diabetes Management
Medical Imaging AI
Upload X-Ray, CT, MRI, or Ultrasound — instant AI-powered diagnostic analysis
94.2%
Diagnostic Accuracy
15+
Conditions Detected
2.3s
Analysis Speed
847K
Images Analyzed
Upload Study
Drop imaging file here or click to upload
X-Ray · CT Scan · MRI · Ultrasound · Mammogram
DICOM · PNG · JPG up to 100MB
DICOM · PNG · JPG up to 100MB
AI Analysis Results
AI analyzing radiograph…
Normal
PRIMARY FINDING
Chest X-Ray
96%
CONFIDENCE
AI Confidence Score
Neg
TB SCREEN
Tuberculosis
Low
PNEUMONIA
Risk Level
AI NARRATIVE REPORT
The chest radiograph demonstrates clear lung fields bilaterally with no evidence of consolidation, infiltrates, or pleural effusions. The cardiac silhouette is within normal limits (cardiothoracic ratio <0.5). No pneumothorax detected. Costophrenic angles are sharp. Bony structures and soft tissues appear unremarkable.
Impression: No acute cardiopulmonary abnormality. Clinical correlation recommended. Standard preventive care protocols advised.
Radiologist Note
AI findings should be reviewed by a qualified radiologist or clinician before clinical decisions. This tool augments, not replaces, expert judgment.
AI Symptom Analysis
Intelligent differential diagnosis powered by Claude — evidence-based triage and DDx generation
Patient & Symptoms
😷 Cough
🌡️ Fever
😮💨 Dyspnea
😰 Fatigue
🤕 Headache
💪 Myalgia
🤧 Rhinorrhea
🥵 Night Sweats
😵 Dizziness
🤮 Nausea
🫀 Chest Pain
🩸 Hemoptysis
Differential Diagnosis
Generating differential…
Triage: Routine Outpatient — Non-Emergency
Patient can be managed in outpatient setting. Review flags for TB exposure before discharge.
01
Upper Respiratory Tract Infection
Classic viral URTI pattern. Duration and symptom constellation highly consistent.
02
Acute Bronchitis
Persistent productive cough with fever. Duration matches typical course.
03
Community-Acquired Pneumonia
Less likely without consolidation on CXR. Night sweats warrant further investigation.
04
Pulmonary Tuberculosis
⚠️ Night sweats + 2-week cough. Requires AFB sputum smear and culture. Notifiable disease.
Recommended Workup
🔬 CBC + differential — assess for leukocytosis
🩻 Chest X-ray — exclude consolidation, TB
🧫 Sputum AFB smear × 2 — if TB considered
🧪 Rapid flu/COVID antigen — per local epidemiology
🩸 CRP + ESR — inflammatory markers
Lab Results Interpreter
AI-powered clinical interpretation with pattern recognition and action recommendations
Complete Blood Count
| Test | Result | Reference Range | Status | AI Interpretation | Action |
|---|---|---|---|---|---|
| Hemoglobin Hgb |
14.2 g/dL | 13.5 – 17.5 g/dL | ✓ Normal | Adequate oxygen carrying capacity | |
| WBC Count Leukocytes |
12.8 ×10³/μL | 4.5 – 11.0 ×10³/μL | ↑ High | Mild leukocytosis — likely acute infection or inflammation | |
| Platelets PLT |
245 ×10³/μL | 150 – 400 ×10³/μL | ✓ Normal | Adequate for hemostasis | |
| Fasting Glucose FBS |
118 mg/dL | 70 – 100 mg/dL | ↑ Elevated | Impaired fasting glucose — prediabetes range. Order HbA1c. | |
| Total Cholesterol TC |
215 mg/dL | <200 mg/dL | ↑ Borderline | Borderline high — lifestyle modification. Consider full lipid panel. | |
| Creatinine Cr |
1.1 mg/dL | 0.7 – 1.3 mg/dL | ✓ Normal | Renal function intact |
🤖 AI Clinical Interpretation
Overall Assessment — Metabolic Syndrome Risk
Mild leukocytosis consistent with acute infection. Elevated fasting glucose indicates prediabetes (IFG). Borderline hypercholesterolaemia. Together, these represent a cluster of metabolic syndrome features. ADA 2024 ACC/AHA 2023
📌 Priority Action: Order HbA1c and fasting lipid panel to complete metabolic workup
📌 Repeat CBC in 1 week post-treatment to track leukocytosis resolution
📌 Calculate 10-year ASCVD risk using ACC/AHA pooled cohort equations
📌 Initiate structured lifestyle counseling: DASH diet, aerobic exercise ≥150 min/week
Risk Snapshot
DIABETES RISK
22%
5-year estimate
CVD RISK
15%
10-year ASCVD
CKD RISK
8%
5-year estimate
STROKE RISK
7%
10-year estimate
Drug Interaction Checker
Real-time polypharmacy screening — mechanism-based alerts with clinical management guidance
Medication List
💊 Warfarin 5mg
💊 Aspirin 100mg
💊 Lisinopril 10mg
💊 Atorvastatin 20mg
Patient Filters
Interaction Report
SEVERE — Warfarin + Aspirin
Risk: Significantly increased hemorrhage risk via additive anticoagulation.
Mechanism: Aspirin inhibits platelet aggregation (COX-1) + displaces warfarin from plasma proteins → potentiates anticoagulation.
Management: Avoid combination unless benefit clearly outweighs risk. If required, use lowest aspirin dose, monitor INR weekly, add PPI for GI protection.
Alternative: Consider clopidogrel if antiplatelet needed. Reassess warfarin indication.
Mechanism: Aspirin inhibits platelet aggregation (COX-1) + displaces warfarin from plasma proteins → potentiates anticoagulation.
Management: Avoid combination unless benefit clearly outweighs risk. If required, use lowest aspirin dose, monitor INR weekly, add PPI for GI protection.
Alternative: Consider clopidogrel if antiplatelet needed. Reassess warfarin indication.
MODERATE — Lisinopril + Aspirin
Risk: NSAIDs/Aspirin may attenuate antihypertensive effect of ACE inhibitors.
Mechanism: Prostaglandin inhibition → sodium retention → reduced ACE inhibitor efficacy.
Management: Monitor BP. Use minimum effective aspirin dose. Consider Paracetamol if analgesia needed.
Mechanism: Prostaglandin inhibition → sodium retention → reduced ACE inhibitor efficacy.
Management: Monitor BP. Use minimum effective aspirin dose. Consider Paracetamol if analgesia needed.
MINOR — Atorvastatin + Aspirin
Risk: No clinically significant interaction identified at standard doses.
Note: Combination is commonly used and generally well-tolerated in cardiovascular risk management.
Note: Combination is commonly used and generally well-tolerated in cardiovascular risk management.
Risk Stratification
Validated clinical risk scores — CVD, Diabetes, Stroke, CKD, and personalized prevention planning
Clinical Parameters
🚬 Smoking
👨👩👧 Family History CVD
🍺 Alcohol >14 units/wk
😴 Sedentary
🫀 Known CVD
🩸 Diabetes
Calculating risk scores…
10-YEAR CVD RISK
15.2%
Intermediate · ACC/AHA
5-YEAR DIABETES
22.8%
High · ADA Criteria
10-YEAR STROKE
8.4%
Low-Mod · Framingham
CKD RISK
12.6%
Moderate · KDIGO
🎯 Prevention Plan
🏃 Exercise: 150 min/week moderate aerobic + 2× resistance training
🥗 Diet: Mediterranean/DASH diet, reduce saturated fats <7% total calories
⚖️ Weight: Target 5–10% weight reduction over 6 months
💊 Pharmacology: Consider moderate-intensity statin if ASCVD >7.5%; discuss metformin if HbA1c >6.5%
📅 Monitor: BP monthly, HbA1c quarterly, fasting lipids every 3 months
Potential Risk Reduction
CVD: 15.2% → 8.2% (↓46%) with optimal therapy
Diabetes: 22.8% → 12.1% (↓47%) with lifestyle
AI Treatment Planner
Evidence-based, guideline-aligned treatment protocols tailored to patient-specific factors
Clinical Input
🫀 Dyslipidemia
🩸 Diabetes
😮💨 Asthma
🫁 COPD
🧠 Depression
🫘 CKD
Generating evidence-based protocol…
Treatment Protocol — Hypertension
ACC/AHA 2023
1st Line — Amlodipine 5mg PO OD
Calcium Channel Blocker
Rationale: CCB preferred for Sub-Saharan African descent patients (NICE NG136). Well-tolerated, once-daily, no electrolyte monitoring required.
Target BP: <130/80 mmHg per ACC/AHA 2023
Titration: Increase to 10mg after 4 weeks if BP not at target
Side Effects: Peripheral edema (5–15%), flushing, headache
Monitoring: BP weekly × 4 weeks, then monthly
Add-on — Atorvastatin 20mg PO OD (bedtime)
HMG-CoA Reductase Inhibitor
Rationale: Borderline hypercholesterolaemia + intermediate CVD risk. Target LDL <100 mg/dL.
Monitoring: Fasting lipid panel in 6 weeks, then 3-monthly. Baseline ALT/AST.
Caution: Avoid grapefruit. Monitor for myopathy (CK if muscle pain).
Warfarin Interaction — Dose Adjust
Adding atorvastatin may increase INR by 20–30%. Recheck INR 5–7 days after initiation and adjust warfarin dose accordingly. BNF Interaction Grade B
Clinical Notes AI
Voice-to-text and AI-drafted SOAP notes, referral letters, and discharge summaries
Input
Generated Note
AI drafting clinical note…
SOAP NOTE — PATIENT #4821 · 20 FEB 2026
S — SUBJECTIVE
42-year-old male presents with a 2-week history of productive cough, low-grade fever, and fatigue. Patient reports three episodes of night sweats. Denies haemoptysis or chest pain. No known TB contacts. Reports adequate oral intake and hydration. Relevant PMHx: Atrial fibrillation on warfarin; Hypertension. Allergy: Penicillin (urticarial rash).
42-year-old male presents with a 2-week history of productive cough, low-grade fever, and fatigue. Patient reports three episodes of night sweats. Denies haemoptysis or chest pain. No known TB contacts. Reports adequate oral intake and hydration. Relevant PMHx: Atrial fibrillation on warfarin; Hypertension. Allergy: Penicillin (urticarial rash).
O — OBJECTIVE
T: 37.8°C · HR: 88 bpm regular · BP: 128/82 mmHg · SpO2: 98% RA · RR: 18/min
Chest: Air entry bilaterally. No crepitations or wheeze. CXR (today): No acute cardiopulmonary pathology. WBC: 12.8 ×10³/μL (mild leukocytosis).
T: 37.8°C · HR: 88 bpm regular · BP: 128/82 mmHg · SpO2: 98% RA · RR: 18/min
Chest: Air entry bilaterally. No crepitations or wheeze. CXR (today): No acute cardiopulmonary pathology. WBC: 12.8 ×10³/μL (mild leukocytosis).
A — ASSESSMENT
1. Acute respiratory tract infection — viral URTI most likely (J06.9). Acute bronchitis considered. Pulmonary TB to be excluded given 2-week course + night sweats (low probability, CXR normal).
2. Mild leukocytosis — consistent with acute infection.
3. Ongoing: Atrial fibrillation on warfarin; Hypertension.
1. Acute respiratory tract infection — viral URTI most likely (J06.9). Acute bronchitis considered. Pulmonary TB to be excluded given 2-week course + night sweats (low probability, CXR normal).
2. Mild leukocytosis — consistent with acute infection.
3. Ongoing: Atrial fibrillation on warfarin; Hypertension.
P — PLAN
Rx: Azithromycin 500mg PO on Day 1, then 250mg OD × 4 days (penicillin allergy precaution).
Ix: Sputum AFB smear × 2 (TB exclusion). Repeat CBC in 1 week. INR check next visit.
Edu: Adequate hydration, rest, paracetamol PRN for fever. Isolate if TB not excluded.
F/U: Review in 5 days or sooner if symptoms worsen. Return precautions given re: haemoptysis, dyspnoea, worsening fever.
Rx: Azithromycin 500mg PO on Day 1, then 250mg OD × 4 days (penicillin allergy precaution).
Ix: Sputum AFB smear × 2 (TB exclusion). Repeat CBC in 1 week. INR check next visit.
Edu: Adequate hydration, rest, paracetamol PRN for fever. Isolate if TB not excluded.
F/U: Review in 5 days or sooner if symptoms worsen. Return precautions given re: haemoptysis, dyspnoea, worsening fever.
Patient History
Longitudinal patient timeline with AI-summarized encounters
👤
Patient History Module
Connect your EMR/EHR (FHIR R4 compatible) to view full patient history, medications, allergies, and encounter summaries.
Follow-Up Tracker
Automated follow-up scheduling with AI-generated patient reminders
📅
Follow-Up Management
Schedule, track, and automate patient follow-ups with intelligent reminders via SMS and email.